A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph Nodes

The bioavailability of a monoclonal antibody (mAb) or another therapeutic protein after subcutaneous (SC) dosing is challenging to predict from first principles, even if the impact of injection site physiology and drug properties on mAb bioavailability is generally understood. We used a physiologica...

Full description

Bibliographic Details
Published in:	Antibodies
Main Authors:	Felix Stader, Cong Liu, Abdallah Derbalah, Hiroshi Momiji, Xian Pan, Iain Gardner, Masoud Jamei, Armin Sepp
Format:	Article
Language:	English
Published:	MDPI AG 2024-08-01
Subjects:	monoclonal antibodies subcutaneous dosing physiologically based pharmacokinetic modeling antigen-presenting cells neonatal Fc receptor (FcRn)
Online Access:	https://www.mdpi.com/2073-4468/13/3/70

Similar Items

FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues
by: Tommy Li, et al.
Published: (2018-10-01)

FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia
by: Michael Sandhu, et al.
Published: (2025-08-01)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
by: Yihan Zhou, et al.
Published: (2023-06-01)

Megalin Orchestrates FcRn Endocytosis and Trafficking
by: Eileen Dahlke, et al.
Published: (2022-12-01)

The neonatal Fc receptor (FcRn) is required for porcine reproductive and respiratory syndrome virus uncoating
by: Kang Yang, et al.
Published: (2025-01-01)

Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice
by: Kenta Haraya, et al.
Published: (2025-12-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

The FcRn from gene to protein and function: comparison between species
by: Luz Belinda Ortiz-Alegría, et al.
Published: (2025-08-01)

Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice
by: Christine Joy I. Bulaon, et al.
Published: (2025-12-01)

FcRN receptor antagonists in the management of myasthenia gravis
by: Vinaya Bhandari, et al.
Published: (2023-08-01)

Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01)

Prediction of the pharmacokinetics, pharmacodynamics and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model.
by: Manoranjenni eChetty, et al.
Published: (2015-01-01)

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023-12-01)

Human FcRn Is a Two-in-One Attachment-Uncoating Receptor for Echovirus 18
by: Xiangpeng Chen, et al.
Published: (2022-08-01)

FcRn-guided antigen trafficking enhances cancer vaccine efficacy
by: Mengyu Hong, et al.
Published: (2025-01-01)

From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases
by: Chu Wei Yang, et al.
Published: (2025-10-01)

Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential
by: Sanghwan Ko, et al.
Published: (2025-04-01)

FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against <i>Brucella</i>
by: Tingting Tian, et al.
Published: (2025-05-01)

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
by: Johannes Reusch, et al.
Published: (2024-12-01)

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
by: E. Sally Ward, et al.
Published: (2022-06-01)

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
by: Trang T. Vu, et al.
Published: (2024-01-01)

Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium
by: Kohei Togami, et al.
Published: (2024-09-01)

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
by: Simone Mester, et al.
Published: (2021-01-01)

Human FcRn can mediate the transport across intestinal mucosal barrier and prolong the half-life of rabbit IgG in vivo
by: Guangchang Pang, et al.
Published: (2015-06-01)

Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
by: Hui‐Ning Li, et al.
Published: (2025-08-01)

Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
by: Jason Tien, et al.
Published: (2023-12-01)

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment
by: Diana Cadena Castaneda, et al.
Published: (2018-09-01)

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties
by: Nilufer P. Seth, et al.
Published: (2025-12-01)

Overexpression of bovine FcRn in mice enhances T-dependent immune responses by amplifying T helper cell frequency and germinal center enlargement in the spleen
by: Zita eSchneider, et al.
Published: (2015-07-01)

Zika Virus Infection and Antibody Neutralization in FcRn Expressing Placenta and Engineered Cell Lines
by: Yanqun Xu, et al.
Published: (2022-11-01)

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network
by: Luqiong Wang, et al.
Published: (2025-10-01)

Oral uptake and persistence of the FnAb-8 protein characterized by in situ radio-labeling and PET/CT imaging
by: Qian Wang, et al.
Published: (2020-11-01)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
by: Geert van Tetering, et al.
Published: (2020-12-01)

Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
by: Yvonne J. Rosenberg, et al.
Published: (2023-04-01)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
by: Liming Liu
Published: (2017-04-01)

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice
by: Jerome Egli, et al.
Published: (2022-12-01)

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
by: Brian C. Mackness, et al.
Published: (2019-10-01)

Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality
by: Nicolas Aubrey, et al.
Published: (2022-08-01)

Study on FcγRn Electrochemical Receptor Sensor and Its Kinetics
by: Dandan Peng, et al.
Published: (2020-07-01)

Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium
by: João P. Martins, et al.
Published: (2022-03-01)